How Pharmacovigilance and Drug Safety Teams Use Virtual Assistants for Adverse Event Intake, Report Preparation, and Regulatory Submission

The Volume Problem in Pharmacovigilance Is Getting Worse

Global adverse event reporting volumes have grown substantially over the past five years. The FDA's MedWatch program received over 2.3 million adverse event reports in fiscal year 2024 — a 14% increase from the prior year — reflecting both genuine safety signal growth and the expansion of mandatory reporting obligations under FAERS and ICH E2B(R3) standards.

For pharmaceutical companies, biotechs, and medical device manufacturers managing post-market safety surveillance programs, this volume growth is creating a structural strain on drug safety teams. Individual case safety reports (ICSRs) — the primary documentation unit of pharmacovigilance — require intake, triage, coding (MedDRA), narrative writing, medical review, and submission within strict regulatory timelines. Expedited reports (serious, unexpected, related adverse events) must be submitted to FDA within 15 calendar days of initial receipt. Missing that window is a regulatory infraction with consequences ranging from warning letters to program delays.

Virtual assistants are being integrated into pharmacovigilance workflows to absorb the high-volume administrative work at the intake and preparation stages — protecting medical reviewer capacity for the judgment-dependent work.

Adverse Event Intake and Triage Support

Adverse event reports arrive through multiple channels simultaneously — consumer hotlines, MedWatch, literature monitoring, clinical trial safety reports, social media monitoring, and spontaneous reports from healthcare professionals. Each report must be acknowledged, logged, assessed for expedited reportability, and routed to the appropriate safety scientist for case processing.

A virtual assistant supporting adverse event intake can:

• Monitor designated AE intake channels — email inboxes, fax queues, and case intake portals — on a defined schedule
• Log new case reports in the safety database or tracking spreadsheet, capturing source, receipt date, product, and initial event description
• Send acknowledgment communications to reporters within required timeframes
• Perform initial reportability triage — flagging cases that meet preliminary criteria for serious, unexpected, or clinical trial spontaneous reports — under safety scientist supervision
• Route triaged cases to the assigned safety scientist with a standardized case briefing
• Track 15-day expedited report windows and generate daily aging reports identifying cases approaching the reporting deadline

This intake support layer allows safety scientists to begin medical assessment immediately rather than spending time on case logging and channel monitoring.

ICSR Narrative Preparation Support

The ICSR narrative — a structured prose summary of the adverse event case that meets ICH E2B and regional health authority requirements — is the core documentation unit of pharmacovigilance. Narrative preparation requires synthesizing source documents (medical records, healthcare professional reports, clinical trial data) into a structured format that captures the patient, event, drug, and outcome information in a complete, accurate, and compliant manner.

Narrative writing at the final stage requires medical expertise, but the preparation work — document collection, data extraction, and draft template population — can be supported by experienced VAs working under safety scientist supervision.

A virtual assistant supporting ICSR preparation can:

• Collect source documents from reporters, clinical sites, or literature databases as directed by the case processor
• Populate case data fields in the safety database (Argus, ArisG, Veeva Vault Safety, or equivalent) from source documents under safety scientist direction
• Prepare draft narrative templates with structured data fields completed, ready for safety scientist narrative writing and medical review
• Track follow-up request status for cases requiring additional information from reporters or healthcare providers
• Log follow-up communications and update case records when additional information is received

Expedited Report Submission Coordination

Once an expedited case has been reviewed and approved by the safety physician, it must be submitted to the applicable health authorities within the regulatory window. The submission process involves E2B file generation, portal submission, acknowledgment monitoring, and documentation of successful submission in the safety database.

For companies with global marketing or clinical trial programs, expedited submissions may be required simultaneously to FDA (15 days), EMA (15 calendar days), Health Canada, TGA, PMDA, and other authorities — each with different submission portals, E2B format versions, and acknowledgment tracking requirements.

A virtual assistant supporting submission coordination can:

• Prepare submission packages for each applicable health authority, following the approved case narrative and E2B file generated by the safety system
• Submit approved cases through the appropriate health authority portals under pharmacovigilance manager oversight
• Track submission acknowledgments and log confirmation in the safety database
• Flag failed submissions or portal errors for immediate escalation to the submission coordinator
• Maintain the submission log as the source of record for regulatory inspection readiness

Protecting Compliance in a High-Stakes Environment

Drug safety teams that have integrated VA support into intake, preparation, and submission workflows consistently report improved timeline adherence, reduced safety scientist overtime, and better inspection readiness. The key is establishing clear SOPs, defined escalation protocols for clinical decisions, and proper access controls aligned with 21 CFR Part 11 requirements.

Stealth Agents provides virtual assistants with pharmacovigilance administrative experience who can be onboarded to safety database workflows, intake protocols, and submission coordination procedures.

Sources

• FDA MedWatch and FAERS, Adverse Event Reporting Volume FY2024
• ICH E2B(R3), Electronic Transmission of Individual Case Safety Reports
• ICH E2D, Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting
• FDA, Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products, 2024
• EMA, Good Pharmacovigilance Practices (GVP) Module VI: Management and Reporting of Adverse Reactions, 2024